Sign up for our free daily newsletter


Get the latest news and some fun stuff
in your inbox every day

Research archive for SYK

Stryker Q4 - Outstanding from MedSurg & Neurotechnology

08 February 2024

Medical device company Stryker demonstrated a robust performance in the fourth quarter, with reported net sales increasing by 11.8% to $5.8 billion thanks to rising demand for elective surgeries. Stryker has been a Vestact-recommended stock since January 2014, exactly a decade ago.

Read more...


Stryker Q2 - Market-beating results

06 November 2023

Last week Stryker, our preferred stock in the medical devices industry, issued market-beating results with revenue of $4.9 billion, up 9.6% year-on-year, and earnings per share of $2.46. Even with that handy beat on revenue and profits, the share price dropped 0.8% on Friday because hip and knee replacement revenue was lower than expected.

Read more...


Stryker Q1 - Solid number from a quality operator

10 August 2023

Last week our medical technology holding Stryker reported solid numbers. Sales increased by 11.2% to $5 billion which resulted in an adjusted earnings per share increase of 12.9% to $2.54. They expect to make just over $10 a share for the full year. That puts the stock on a forward multiple of 28 times earnings. This is pretty standard for a quality operation showing consistent growth in a thriving industry.

Read more...


Stryker Q4 - Back to double digit growth

11 May 2023

A week ago Stryker reported strong first-quarter earnings and provided an upbeat outlook for the fiscal year. The medical device company's sales came in at $4.80 billion, up 11.8% year-over-year (or 14% in constant currency), surpassing the consensus estimate of $4.56 billion.

Read more...


Stryker At All Time Highs

12 April 2023

One of our portfolio shares traded at an all-time high yesterday - medical device maker Stryker. We added them to our recommended portfolio in late January 2014. The chart below shows what they have done since then.

Read more...


Stryker Q3 - Earnings & Revenue Top Estimates

01 February 2023

After a tough 2022, this earnings season is a bit more tense than usual. Vestact-recommended medical device company Stryker reported numbers after the market's close last night, thankfully beating both top and bottom line expectations. As mentioned above, the stock rose smartly in after-hours trading.

Read more...


Styker Q2 - Adjusted Outlook

03 November 2022

On Monday night, Stryker, the medical device business, released their numbers for the third quarter of the year. My son had his tonsils taken out the other day. Whilst in the theatre I was pleased to see a Stryker surgical monitor (like the picture below), which was linked to Stryker equipment used to perform the surgery. All went well.

Read more...


Stryker Launches Hip Fracture Nailing System

05 September 2022

Stryker is always innovating in the medical devices arena. They recently launched the Gamma4 Hip Fracture Nailing System which according to the company does the following.

Read more...


Stryker Q1 - Steady Growth

04 August 2022

Medical device-maker Stryker has been a Vestact-recommended stock since January 2014. In that time they've made good progress, growing sales from around $10 billion a year to $18 billion. Profits have risen steadily too, and so has the share price.

Read more...


Stryker Struggles With Chips

01 April 2022

We have a client who works in the medical devices industry and he sent me an update from Stryker, who are struggling with chip shortages. Stryker has to bid for these chips through a broker, and that's crimping margins. They expect this to continue throughout the year.

Read more...


Stryker Q4 - Double Digit Growth Amid Delay In Elective Surgery

02 February 2022

Medical technology company Stryker reported mixed fourth-quarter results last week. Not for the first time, Covid delayed many elective surgical procedures. The company reported revenues of $4.70 billion and profits of $662 million for the quarter, up 10.3% and 16.5% year-on-year, respectively.

Read more...


Stryker Buys Vocera

10 January 2022

On Thursday Stryker announced that they are buying Vocera Communications for $3 billion. Here is a high-level description of the business: "Vocera caters to nearly 1 900 hospitals, allowing healthcare workers to communicate and collaborate with co-workers and engage with patients and their families". Looking at their website, they seem to be a hospital management system making it easy for staff members to interact with each other and have easy access to patient information.

Read more...


Stryker Q3 - Good Sales Growth

03 November 2021

Stryker was hit hard by Covid because elective surgeries were halted and hospitals' priorities changed drastically. As the world slowly normalises, the recovery has been lumpy. People needing hip and knee replacements have booked appointments in droves but theatre staff are in short supply as Covid variants keep popping up.

Read more...


Stryker Q1 - Back In Business

04 August 2021

Medical device-maker Stryker reported second-quarter numbers last week. The results were fine, and the stock moved to a new all-time high above $270 per share.

Read more...


Styker Balloons

14 July 2021

Picture this. You are a Vestact client and you wake up on a Saturday morning, make yourself a coffee and check your emails. Your weekly mini-statement pops up and you scroll through it briefly. Looking good, nice to see Stryker above $260 a share again. You delete the email and go for a run.

Read more...


Other recommended stocks     Older stories...